Alector Inc
ALEC
Company Profile
Business description
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Contact
131 Oyster Point Boulevard
Suite 600
South San FranciscoCA94080
USAT: +1 415 231-5660
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
163
Stocks News & Analysis
stocks
Investment decisions in overvalued bank drive strong results
Shares fall despite a broadly unchanged outlook.
stocks
Overvalued ASX share hurt by normalising conditions
Investors overly optimisitc about future prospects.
stocks
After earnings, is Amazon stock a buy, a sell, or fairly valued?
With temperature on tariffs easing and a raised fair value estimate, here’s what we think of Amazon’s results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,097.50 | 40.60 | 0.45% |
| CAC 40 | 7,950.18 | 14.59 | -0.18% |
| DAX 40 | 23,569.96 | 164.06 | -0.69% |
| Dow JONES (US) | 46,987.10 | 74.80 | 0.16% |
| FTSE 100 | 9,682.57 | 53.21 | -0.55% |
| HKSE | 26,398.20 | 156.37 | 0.60% |
| NASDAQ | 23,004.54 | 49.46 | -0.21% |
| Nikkei 225 | 50,760.50 | 484.13 | 0.96% |
| NZX 50 Index | 13,579.86 | 19.35 | -0.14% |
| S&P 500 | 6,728.80 | 8.48 | 0.13% |
| S&P/ASX 200 | 8,823.20 | 31.40 | 0.36% |
| SSE Composite Index | 3,996.26 | 1.29 | -0.03% |